arrow
I

Irena Loryan

Uppsala University
H指数:17
被引数:990

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An exploratory pharmacokinetic-pharmacodynamic analysis of ceftazidime-avibactam and various blood biomarkers in patients with hospital-acquired pneumonia or ventilator-associated pneumonia caused by Klebsiella pneumoniae

对由肺炎克雷伯菌引起的医院获得性肺炎或呼吸机相关性肺炎患者中ceftazidime-avibactam和各种血液生物标志物的探索性药代动力学-药效学分析

2026-08-010
PRE
Evaluation of sNfL as a Biomarker for Paclitaxel-Induced Peripheral Neurotoxicity Through an Integrated PKPD Model

通过整合的PKPD模型评估sNfL作为紫杉醇诱导周围神经毒性的生物标志物

2026-03-130
OAAI
Comparative analysis of the uptake of the H+/OC antiporter substrate oxycodone across and into brain endothelial and parenchymal cells with in vitro–in vivo extrapolation

H+/OC反向转运蛋白底物羟考酮(oxycodone)在体外-体内外推研究中,于脑内皮细胞和脑实质细胞之间及内部的摄取比较分析

2025-10-310
OAAI
The challenge to identify sensitive safety biomarkers of peripheral neurotoxicity in the rat: A collaborative effort across industry and academia (IMI NeuroDeRisk project)
2025-01-010
OAAI
Preclinical and emerging Phase 1 study data indicates that novel deuterated MET kinase inhibitor DO-2 mitigates the side effects seen with current approved MET kinase inhibitors: Preventing deleterious ′de-hinging′ to improve tolerability
2023-12-010
PRE
Neurofilament light chain in plasma as a sensitive diagnostic biomarker of peripheral neurotoxicity: In Vivo mouse studies with oxaliplatin and paclitaxel- NeuroDeRisk project
2023-11-012
OAAI
Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain-a Game Changing Parameter for CNS Drug Discovery and Development

未结合的脑-血浆分配系数,Kp,uu,脑-CNS药物发现和开发的游戏改变参数

2022-04-1162
OAAI